{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T20:17:25Z","timestamp":1791404245085,"version":"4.3.3"},"reference-count":29,"publisher":"European Respiratory Society (ERS)","issue":"1","license":[{"start":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T00:00:00Z","timestamp":1759968000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/publications.ersnet.org\/user-licence"}],"funder":[{"name":"MTPConnect Project Fund Program","award":["PRJ2017-57"],"award-info":[{"award-number":["PRJ2017-57"]}]},{"name":"BHP Blue Sky Award"},{"name":"Australian Medical Research Future Fund","award":["MRF1152376"],"award-info":[{"award-number":["MRF1152376"]}]}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["Eur Respir J"],"accepted":{"date-parts":[[2025,9,12]]},"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Pulmonary exacerbations pose a significant clinical burden on people with cystic fibrosis (pwCF). Whether management of exacerbations should change in the context of modulator therapy is unclear. We describe the characteristics, treatment and lung function outcomes of pulmonary exacerbations requiring intravenous antibiotic therapy (PERITs) in a contemporary Australian cohort of pwCF, in an era of rapidly broadening access to modulator therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>PwCF receiving care at 11 Australian specialist centres were prospectively enrolled between 14 October 2020 and 9 October 2024. Spirometry data and treatments received during a PERIT were collected systematically.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 982 pwCF were enrolled, with 593 PERITs recorded in 323 individuals. The median (interquartile range) age at PERIT start was 12 (7\u201317)\u2005years and the mean\u00b1\n                      <jats:sc>sd<\/jats:sc>\n                      baseline forced expiratory volume in 1\u2005s (FEV\n                      <jats:sub>1<\/jats:sub>\n                      ) % predicted across PERITs was 80\u00b121%. Approximately 62% (n=366) of PERITs occurred in people receiving modulator therapy. Intravenous tobramycin (63%) and piperacillin-tazobactam (43%) were the most frequently used antibiotics. Among participants with spirometry at baseline and at Day 7 (n=296) or Day 60 (n=383), 41% (n=120) and 44% (n=169) were below their baseline at Day 7 and Day 60 after commencing treatment, respectively; 8% were &gt;10% below their baseline FEV\n                      <jats:sub>1<\/jats:sub>\n                      % predicted at both time-points. Recovery patterns were consistent regardless of baseline lung function,\n                      <jats:italic>Pseudomonas aeruginosa<\/jats:italic>\n                      colonisation or modulator use.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The pattern and magnitude of lung function impairment during PERITs is similar among those receiving and not receiving modulator therapy. This underscores the continued need for evidence to help clinicians balance treatment burden against the risk of irreversible loss of lung function.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1183\/13993003.01349-2025","type":"journal-article","created":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:55:15Z","timestamp":1760028915000},"page":"2501349","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Characteristics, treatment and lung function outcomes of pulmonary exacerbations in cystic fibrosis: insights from the BEAT-CF cohort"],"prefix":"10.1183","volume":"67","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4516-4127","authenticated-orcid":false,"given":"Parveen","family":"Fathima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Marsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6000-3180","authenticated-orcid":false,"given":"Shivanthan","family":"Shanthikumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheila","family":"Sivam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Jaffe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiran","family":"Selvadurai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ameneh","family":"Khatami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geshani","family":"Jayasuriya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Norman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Tai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy","family":"Burr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siobhain","family":"Mulrennan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Snelling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9","family":"Schultz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2025,10,9]]},"reference":[{"key":"2026010801350829000_67.1.2501349.1","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1055\/s-0042-1760250","article-title":"Diagnosis and management of cystic fibrosis exacerbations","volume":"44","author":"Milinic","year":"2023","journal-title":"Semin Respir Crit Care Med"},{"key":"2026010801350829000_67.1.2501349.2","doi-asserted-by":"crossref","first-page":"102214","DOI":"10.1016\/j.coph.2022.102214","article-title":"Overview of CF lung pathophysiology","volume":"64","author":"Cabrini","year":"2022","journal-title":"Curr Opin Pharmacol"},{"key":"2026010801350829000_67.1.2501349.3","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1080\/17476348.2020.1778469","article-title":"The role of inflammation in cystic fibrosis pulmonary exacerbations","volume":"14","author":"Houston","year":"2020","journal-title":"Expert Rev Respir Med"},{"key":"2026010801350829000_67.1.2501349.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2020.09.084"},{"key":"2026010801350829000_67.1.2501349.5","doi-asserted-by":"crossref","first-page":"486","DOI":"10.3390\/antibiotics10050486","article-title":"Treatment of pulmonary disease of cystic fibrosis: a comprehensive review","volume":"10","author":"Gir\u00f3n Moreno","year":"2021","journal-title":"Antibiotics"},{"key":"2026010801350829000_67.1.2501349.6","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.jcf.2024.04.004","article-title":"Update on the diagnosis and management of cystic fibrosis pulmonary exacerbations","volume":"23","author":"Cogen","year":"2024","journal-title":"J Cyst Fibros"},{"key":"2026010801350829000_67.1.2501349.7","unstructured":"Ahern S , Pourghaderi AR , Ruseckaite R , et al. The ACFDR Registry Annual Report, 2023. 2024. www.cysticfibrosis.org.au\/wp-content\/uploads\/2024\/07\/ACFDR_2023_Annual-Report.pdf Date last accessed: 20 September 2025."},{"key":"2026010801350829000_67.1.2501349.8","doi-asserted-by":"publisher","DOI":"10.1099\/mic.0.001553"},{"key":"2026010801350829000_67.1.2501349.9","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200812-1845PP"},{"key":"2026010801350829000_67.1.2501349.10","doi-asserted-by":"publisher","DOI":"10.1136\/thorax-2023-220100"},{"key":"2026010801350829000_67.1.2501349.11","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/s13063-023-07076-8","article-title":"BEAT CF pulmonary exacerbations core protocol for evaluating the management of pulmonary exacerbations in people with cystic fibrosis","volume":"24","author":"Schultz","year":"2023","journal-title":"Trials"},{"key":"2026010801350829000_67.1.2501349.12","doi-asserted-by":"crossref","first-page":"108080","DOI":"10.1016\/j.rmed.2025.108080","article-title":"BEAT-CF (Bayesian Evidence Adaptive Treatment for people with Cystic Fibrosis): description of a prospective cohort for nested studies in cystic fibrosis","volume":"241","author":"Fathima","year":"2025","journal-title":"Respir Med"},{"key":"2026010801350829000_67.1.2501349.13","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00080312"},{"key":"2026010801350829000_67.1.2501349.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2009.04.003"},{"key":"2026010801350829000_67.1.2501349.15","doi-asserted-by":"publisher","DOI":"10.1187\/cbe.16-04-0148"},{"key":"2026010801350829000_67.1.2501349.16","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.jcf.2017.04.003","article-title":"Standardized Treatment of Pulmonary Exacerbations (STOP) study: physician treatment practices and outcomes for individuals with cystic fibrosis with pulmonary exacerbations","volume":"16","author":"West","year":"2017","journal-title":"J Cyst Fibros"},{"key":"2026010801350829000_67.1.2501349.17","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200909-1421OC"},{"key":"2026010801350829000_67.1.2501349.18","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1002\/ppul.24577","article-title":"Lung function changes before and after pulmonary exacerbation antimicrobial treatment in cystic fibrosis","volume":"55","author":"Wagener","year":"2020","journal-title":"Pediatr Pulmonol"},{"key":"2026010801350829000_67.1.2501349.19","doi-asserted-by":"crossref","first-page":"101378","DOI":"10.1016\/j.conctc.2024.101378","article-title":"Baseline-dependent improvement in CF studies, plausibility of bias","volume":"42","author":"Graham","year":"2024","journal-title":"Contemp Clin Trials Commun"},{"key":"2026010801350829000_67.1.2501349.20","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.jcf.2017.04.005","article-title":"Standardized Treatment of Pulmonary Exacerbations (STOP) study: observations at the initiation of intravenous antibiotics for cystic fibrosis pulmonary exacerbations","volume":"16","author":"Sanders","year":"2017","journal-title":"J Cyst Fibros"},{"key":"2026010801350829000_67.1.2501349.21","doi-asserted-by":"publisher","DOI":"10.1136\/bmjresp-2021-000956"},{"key":"2026010801350829000_67.1.2501349.22","first-page":"CD009730","article-title":"Intravenous antibiotics for pulmonary exacerbations in people with cystic fibrosis","volume":"7","author":"Hurley","year":"2025","journal-title":"Cochrane Database Syst Rev"},{"key":"2026010801350829000_67.1.2501349.23","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1513\/AnnalsATS.202111-1294OC","article-title":"Clinical outcomes of antipseudomonal versus other antibiotics among children with cystic fibrosis without Pseudomonas aeruginosa","volume":"19","author":"Cogen","year":"2022","journal-title":"Ann Am Thorac Soc"},{"key":"2026010801350829000_67.1.2501349.24","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.jcf.2020.11.020","article-title":"Ototoxicity in cystic fibrosis patients receiving intravenous tobramycin for acute pulmonary exacerbation: ototoxicity following tobramycin treatment","volume":"20","author":"Harruff","year":"2021","journal-title":"J Cyst Fibros"},{"key":"2026010801350829000_67.1.2501349.25","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2014-206750"},{"key":"2026010801350829000_67.1.2501349.26","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202102-0461OC"},{"key":"2026010801350829000_67.1.2501349.27","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.cct.2017.11.012","article-title":"Study design considerations for the Standardized Treatment of Pulmonary Exacerbations 2 (STOP2): a trial to compare intravenous antibiotic treatment durations in CF","volume":"64","author":"Heltshe","year":"2018","journal-title":"Contemp Clin Trials"},{"key":"2026010801350829000_67.1.2501349.28","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1002\/ppul.25925","article-title":"Evaluating FEV1 decline in diagnosis and management of pulmonary exacerbations in children with cystic fibrosis","volume":"57","author":"Bouzek","year":"2022","journal-title":"Pediatr Pulmonol"},{"key":"2026010801350829000_67.1.2501349.29","doi-asserted-by":"crossref","first-page":"3212","DOI":"10.1002\/ppul.27176","article-title":"Treatment of small as well as large declines in lung function enhances recovery to baseline in people with CF","volume":"59","author":"Schechter","year":"2024","journal-title":"Pediatr Pulmonol"}],"container-title":["European Respiratory Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/13993003.01349-2025","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T09:35:17Z","timestamp":1767864917000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/13993003.01349-2025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,9]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1,8]]},"published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1183\/13993003.01349-2025"],"URL":"https:\/\/doi.org\/10.1183\/13993003.01349-2025","relation":{},"ISSN":["0903-1936","1399-3003"],"issn-type":[{"value":"0903-1936","type":"print"},{"value":"1399-3003","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,9]]}}}